Compare Stocks: DRCT, SLGL, TRAW, and HAO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DRCT Direct Digital	$0.25 +0.2%	$1.56	$0.25 ▼ $92.40	$200K	5.33	328,376 shs	1,197 shs
HAO Haoxi Health Technology	$1.95 -8.9%	$2.94	$1.95 ▼ $4,352.00	$783K	-1.08	96,652 shs	19,259 shs
SLGL Sol-Gel Technologies	$65.72 -0.1%	$70.59	$28.81 ▼ $97.97	$215.46M	1.14	40,420 shs	59,516 shs
TRAW Traws Pharma	$0.38 -0.2%	$0.52	$0.36 ▼ $3.23	$5.79M	1.52	1.63 million shs	83,739 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DRCT Direct Digital	+0.24%	-26.47%	-85.29%	-90.46%	-99.67%
HAO Haoxi Health Technology	-8.88%	-9.72%	-29.09%	-43.84%	-99.93%
SLGL Sol-Gel Technologies	-0.14%	-5.44%	+10.86%	-18.41%	+63.75%
TRAW Traws Pharma	-0.19%	-6.28%	-24.77%	-27.69%	-87.38%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DRCT Direct Digital	$0.25 +0.2%	$1.56	$0.25 ▼ $92.40	$200K	5.33	328,376 shs	1,197 shs
HAO Haoxi Health Technology	$1.95 -8.9%	$2.94	$1.95 ▼ $4,352.00	$783K	-1.08	96,652 shs	19,259 shs
SLGL Sol-Gel Technologies	$65.72 -0.1%	$70.59	$28.81 ▼ $97.97	$215.46M	1.14	40,420 shs	59,516 shs
TRAW Traws Pharma	$0.38 -0.2%	$0.52	$0.36 ▼ $3.23	$5.79M	1.52	1.63 million shs	83,739 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DRCT Direct Digital	+0.24%	-26.47%	-85.29%	-90.46%	-99.67%
HAO Haoxi Health Technology	-8.88%	-9.72%	-29.09%	-43.84%	-99.93%
SLGL Sol-Gel Technologies	-0.14%	-5.44%	+10.86%	-18.41%	+63.75%
TRAW Traws Pharma	-0.19%	-6.28%	-24.77%	-27.69%	-87.38%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DRCT Direct Digital	1.00	Sell	N/A	N/A
HAO Haoxi Health Technology	1.00	Sell	N/A	N/A
SLGL Sol-Gel Technologies	3.00	Buy	$197.50	200.52% Upside
TRAW Traws Pharma	1.80	Reduce	$1.00	165.96% Upside

Current Analyst Ratings Breakdown

Latest DRCT, SLGL, TRAW, and HAO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/19/2026	SLGL Sol-Gel Technologies	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$110.00
10/15/2026	SLGL Sol-Gel Technologies	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Strong-Buy
10/14/2026	SLGL Sol-Gel Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight
10/6/2026	HAO Haoxi Health Technology	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D) ➝ Sell (D-)
10/6/2026	SLGL Sol-Gel Technologies	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/25/2026	DRCT Direct Digital	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
9/1/2026	SLGL Sol-Gel Technologies	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
8/26/2026	TRAW Traws Pharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
8/18/2026	TRAW Traws Pharma	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Neutral	$1.00

(Data available from 10/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DRCT Direct Digital	$30.91M	0.01	N/A	N/A	($18.82) per share	-0.01
HAO Haoxi Health Technology	$54.83M	0.01	N/A	N/A	$48.78 per share	0.04
SLGL Sol-Gel Technologies	$19.39M	11.08	N/A	N/A	$8.19 per share	8.02
TRAW Traws Pharma	$2.79M	2.07	$0.77 per share	0.49	($0.07) per share	-5.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DRCT Direct Digital	-$18.95M	-$156.85	N/A	N/A	N/A	-74.38%	N/A	-68.48%	11/5/2026 (Estimated)
HAO Haoxi Health Technology	-$9.54M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SLGL Sol-Gel Technologies	-$6.13M	-$5.64	N/A	N/A	N/A	-910.14%	-44.05%	-36.96%	11/19/2026 (Estimated)
TRAW Traws Pharma	$9.17M	-$1.74	N/A	N/A	N/A	N/A	-23,868.92%	-165.52%	11/12/2026 (Estimated)

Latest DRCT, SLGL, TRAW, and HAO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/19/2026	N/A	SLGL Sol-Gel Technologies	-$2.0745	N/A	N/A	N/A	$0.15 million	N/A
11/12/2026	Q3 2026	TRAW Traws Pharma	-$0.21	N/A	N/A	N/A	$2.71 million	N/A
11/5/2026	Q3 2026	DRCT Direct Digital	-$3.19	N/A	N/A	N/A	$8.50 million	N/A
8/21/2026	Q2 2026	SLGL Sol-Gel Technologies	-$2.36	-$1.13	+$1.23	-$1.13	$0.08 million	$0.59 million
8/14/2026	Q2 2026	TRAW Traws Pharma	-$0.3350	-$0.16	+$0.1750	-$0.16	N/A	N/A
8/12/2026	Q2 2026	DRCT Direct Digital	-$9.60	-$5.78	+$3.82	-$5.78	$8.84 million	$7.83 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DRCT Direct Digital	N/A	N/A	N/A	N/A	N/A
HAO Haoxi Health Technology	$0.70	36.00%	N/A	N/A	N/A
SLGL Sol-Gel Technologies	N/A	N/A	N/A	N/A	N/A
TRAW Traws Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DRCT Direct Digital	N/A	0.14	0.14
HAO Haoxi Health Technology	N/A	4.53	4.53
SLGL Sol-Gel Technologies	N/A	10.37	10.37
TRAW Traws Pharma	N/A	0.93	0.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DRCT Direct Digital	4.02%
HAO Haoxi Health Technology	N/A
SLGL Sol-Gel Technologies	26.18%
TRAW Traws Pharma	7.95%

Insider Ownership

Company	Insider Ownership
DRCT Direct Digital	25.57%
HAO Haoxi Health Technology	N/A
SLGL Sol-Gel Technologies	66.51%
TRAW Traws Pharma	7.57%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DRCT Direct Digital	60	803,000	598,000	Not Optionable
HAO Haoxi Health Technology	28	366,000	N/A	N/A
SLGL Sol-Gel Technologies	28	3.27 million	1.10 million	No Data
TRAW Traws Pharma	7	15.37 million	14.21 million	No Data

DRCT, SLGL, TRAW, and HAO Headlines

Recent News About These Companies

Traws Pharma, Inc. (NASDAQ:TRAW) Stock Rated "Reduce" by Wall Street Brokerages

October 18, 2026 | americanbankingnews.com

Traws Pharma (NASDAQ:TRAW) versus Rafael (NYSE:RFL) Critical Review

October 17, 2026 | americanbankingnews.com

Traws Pharma shares rise after Q2 loss comes in better than expected

August 17, 2026 | finance.yahoo.com

Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights

August 14, 2026 | globenewswire.com

Traws Pharma Announces New At-The-Market Offering Program

July 10, 2026 | tipranks.com

Traws Pharma Stock Dividends | NASDAQ:TRAW | Benzinga

July 8, 2026 | benzinga.com

Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program

June 22, 2026 | globenewswire.com

Outlook for Bucks County biotech take another hit with second setback for flu drug

June 15, 2026 | bizjournals.com

Traws defers midphase flu study after negative regulatory review

June 15, 2026 | fiercebiotech.comF

Micron, Nebius surge premarket; Traws Pharma tumbles

June 15, 2026 | finance.yahoo.com

Traws Pharma shares slide after UK regulator postpones influenza study

June 15, 2026 | msn.com

Why did TRAW stock slump 28% after hours?

June 13, 2026 | msn.com

Traws Pharma Defers Phase 2a Study of Tivoxavir Marboxil Following UK Regulatory Review

June 12, 2026 | quiverquant.comQ

Traws Pharma Provides Regulatory Update on Influenza Program

June 12, 2026 | globenewswire.com

Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks

May 27, 2026 | globenewswire.com

Traws Pharma Updates ATM Equity Offering Prospectus Supplements

May 26, 2026 | tipranks.com

Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results

May 15, 2026 | globenewswire.com

Traws Pops on Hantavirus Research

May 9, 2026 | baystreet.ca

A hantavirus update has sent this nano-cap biotech stock surging today – here’s why retail sees potential 20x gains

May 9, 2026 | msn.com

Traws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship Outbreak

May 8, 2026 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRCT, SLGL, TRAW, and HAO Company Descriptions

Direct Digital NASDAQ:DRCT

$0.25 +0.00 (+0.24%)

As of 10/21/2026 10:15 AM Eastern

Direct Digital Holdings, Inc. operates as an end-to-end full-service programmatic advertising platform. The company's platform primarily focuses on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy- and sell-side of the digital advertising ecosystem. It serves various industry verticals, such as travel, healthcare, education, financial services, consumer products, and other sectors with a focus on small and mid-sized businesses. The company was founded in 2018 and is headquartered in Houston, Texas.

Haoxi Health Technology NASDAQ:HAO

$1.95 -0.19 (-8.88%)

Closing price 10/21/2026 04:00 PM Eastern

Extended Trading

$1.90 -0.05 (-2.77%)

As of 05:59 AM Eastern

Haoxi Health Technology Limited, through its subsidiaries, provides online marketing solutions in China. It offers online marketing solutions, including online short video marketing solutions to advertisers through its media partners; and customized marketing solutions by planning, producing, placing, and optimizing online ads to help advertisers acquire, convert, and retain consumers on various online media platforms. The company places its ads through mainstream online short video and social media platforms, such as Toutiao, Douyin, WeChat, and Sina Weibo. It serves advertiser client base primarily in the healthcare industry. The company was founded in 2018 and is based in Beijing, China.

Sol-Gel Technologies NASDAQ:SLGL

$65.72 -0.09 (-0.14%)

Closing price 10/21/2026 04:00 PM Eastern

Extended Trading

$64.80 -0.92 (-1.40%)

As of 04:09 AM Eastern

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Traws Pharma NASDAQ:TRAW

$0.38 0.00 (-0.19%)

Closing price 10/21/2026 04:00 PM Eastern

Extended Trading

$0.39 +0.02 (+4.52%)

As of 05:30 AM Eastern

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DRCT, SLGL, TRAW, and HAO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DRCT, SLGL, TRAW, and HAO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DRCT, SLGL, TRAW, and HAO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRCT, SLGL, TRAW, and HAO Company Descriptions

Direct Digital NASDAQ:DRCT

Haoxi Health Technology NASDAQ:HAO

Sol-Gel Technologies NASDAQ:SLGL

Traws Pharma NASDAQ:TRAW

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DRCT, SLGL, TRAW, and HAO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DRCT, SLGL, TRAW, and HAO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DRCT, SLGL, TRAW, and HAO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRCT, SLGL, TRAW, and HAO Company Descriptions

Direct Digital NASDAQ:DRCT

Haoxi Health Technology NASDAQ:HAO

Sol-Gel Technologies NASDAQ:SLGL

Traws Pharma NASDAQ:TRAW

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools